Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Jones Lang LaSalle Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B). The key difference: Halozyme Therapeutics Inc. Common Stock and Jones Lang LaSalle Inc are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Jones Lang LaSalle Inc for 71 Days on average.
| HALO | JLL | |
|---|---|---|
Market Cap | $12.58B | $13.95B |
Volume | 2,179,278 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $115.22 | $392.79 |
52-Week Low | $61.63 | $280.16 |
Typical Hold Time | 1 Days | 71 Days |
Enterprise Value | $14.49B | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JLL trades at $303.14, up 2.18% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $26.12B in 2025 and improving profit margins. Analyst consensus remains bullish with a $450.50 price target, though technical indicators suggest near-term caution.
JLL presents a compelling value opportunity with attractive valuation ratios (P/E 14.54, P/S 0.53) and consistent earnings outperformance. Key risks include real estate market cyclicality and competitive pressures, but strong institutional support and strategic acquisitions support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
